The critical role of exercise in the GLP-1 era

You Already Know GLP-1 Drugs Are Changing Obesity Treatment. Here's What's Still Missing.

If you've been following obesity and weight management news lately, you've probably heard a lot about GLP-1 receptor agonists like semaglutide and tirzepatide. They work. The data is clear. But a new perspective published in JAMA is raising a question that doesn't get nearly enough attention: what happens to exercise when patients are relying on these medications to manage their weight?

Honestly, it's a question the medical community should have been asking sooner.

What GLP-1 Medications Actually Do to the Body

GLP-1 receptor agonists work by mimicking a gut hormone that regulates appetite and blood sugar. They slow gastric emptying, reduce hunger signals, and help people eat significantly less. The weight loss results can be dramatic.

But here's the thing. Weight loss and fat loss aren't exactly the same thing.

Research consistently shows that rapid weight loss without adequate physical activity leads to muscle loss alongside fat loss. That's a problem. Losing muscle mass can slow metabolism, reduce strength, and increase the risk of falls and functional decline, especially in older adults.

The National Institutes of Health has documented significant lean mass reduction in GLP-1 trials. This isn't a minor side note. It's a central concern that should be shaping how clinicians prescribe these drugs.

The Muscle Loss Problem Nobody's Talking About Enough

To be fair, some patients and providers are aware of this. But awareness and action are two different things.

Muscle is metabolically active tissue. When you lose it, your resting calorie burn drops. That makes long-term weight maintenance significantly harder. So a medication that helps you lose 15-20% of your body weight could, without exercise, leave you in a worse metabolic position over time.

Resistance training, specifically, helps preserve lean muscle during periods of caloric restriction. That's not an opinion. That's exercise physiology.

Why Cardiovascular Health Still Needs Attention

GLP-1 drugs do show cardiovascular benefits in clinical trials. The SELECT trial, for example, demonstrated reduced risk of major cardiovascular events in people with obesity who took semaglutide. That's significant.

But aerobic exercise has benefits that no medication fully replicates. Improved VO2 max, better endothelial function, reduced blood pressure, and mood regulation are all tied to consistent cardio. These aren't redundant with drug therapy. They're complementary.

Why Patients Aren't Exercising More on GLP-1s

You'd think losing weight would make people more motivated to move. And sometimes it does. But the reality is messier.

GLP-1 medications often cause nausea, fatigue, and gastrointestinal discomfort, especially in the early months. That makes exercise feel genuinely difficult. Patients aren't being lazy. They're dealing with real side effects.

And then there's the structural problem. Many prescribers don't have the training, time, or resources to integrate meaningful exercise counseling into their practice. A 15-minute appointment focused on titrating a medication dose doesn't leave room for a nuanced conversation about progressive resistance training.

The Prescriber Gap Is Real

The JAMA perspective makes this point directly. There's a gap between what we know about exercise and what actually gets communicated to patients in clinical settings.

Exercise counseling, when it happens at all, is often vague. "Try to be more active" isn't a prescription. It's a suggestion. And suggestions don't change behavior the way structured, specific plans do.

Patients deserve better than that. And straight up, the system needs to do more to support it.

Behavioral Barriers Are Underestimated

Even when patients want to exercise, the barriers are real. Chronic pain, limited mobility, lack of access to safe spaces, time constraints, low confidence. These don't disappear because someone starts a GLP-1 medication.

This is where exercise physiologists, physical therapists, and certified health coaches could fill a critical role. But they're often not part of the obesity care team. That's a structural failure, not a patient failure.

What a Smarter Approach to Exercise in Obesity Care Looks Like

The good news is we actually know what works. The problem is implementation.

Mayo Clinic recommends a combination of aerobic activity and strength training for sustainable weight management. That's not a new finding. But applying it in the context of GLP-1 therapy requires some specific thinking.

For patients on these medications, resistance training should probably be prioritized early. The goal isn't just calorie burn. It's protecting the muscle mass that's at risk during aggressive weight loss phases.

Building a Realistic Exercise Plan During GLP-1 Therapy

Patients just starting GLP-1 medications shouldn't feel pressure to launch a full workout regimen immediately. The first weeks are often rough. But a gradual, progressive approach can work.

Some practical elements that actually help:

Starting with two to three resistance training sessions per week, even using bodyweight exercises
Adding short walks, 10 to 15 minutes, to manage GI discomfort and improve insulin sensitivity
Working with a physical therapist or certified trainer who understands medication-related fatigue
Tracking protein intake alongside exercise, since muscle preservation requires adequate dietary protein

None of this is revolutionary. But it's being overlooked at scale.

Long-Term Sustainability Is the Whole Point

Here's where I'll offer a mild criticism of how GLP-1 success is being measured. Weight loss numbers get the headlines. Muscle mass preservation, functional strength, and exercise capacity rarely do.

If a patient loses 40 pounds but loses significant muscle and stops being physically active, is that a complete success? I'd argue no. And I think more clinicians are starting to agree.

Some people also explore supportive supplements during weight management phases. If you're curious about how certain products are marketed for this purpose, our review of FitSpresso and its claimed effects on metabolism and energy offers a grounded look at the evidence.

The Bottom Line on Exercise and GLP-1 Therapy

GLP-1 receptor agonists are a genuine advance in obesity treatment. Nobody credible is arguing otherwise.

But medication alone isn't a complete strategy. Exercise preserves muscle, supports cardiovascular health, improves mental wellbeing, and makes long-term weight maintenance far more achievable. These aren't optional extras. They're central to what good obesity care should look like.

The JAMA perspective is right to push for better integration of physical activity into these treatment plans. Whether the healthcare system responds effectively remains to be seen. And that, honestly, is the harder problem.

If you're navigating weight management and want to understand how various approaches, including exercise and supplements, are being evaluated, our breakdown of Flash Burn and what the evidence actually says might be worth reading alongside your conversations with your provider.